1st Quarter - Termination

MS. TAMI WAHL for ROCK & ASSOCIATES

Period 1st Quarter 2019 Filed Apr 5, 2019 Signed by Tami L. Wahl

Official filing
Firm
MS. TAMI WAHL
Client
ROCK & ASSOCIATES
Income
$15,000
Expenses
—
Terminated
Mar 1, 2019

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

Appropriations to fund the implementation of regulations impacting pharmacy compounding.

LobbyistCovered position, as disclosed
JAMES ROCK —
TAMI WAHL —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Pharmacy PHA

Legislation impacting the operation of pharmacy compounding, and access to compounded medications.

LobbyistCovered position, as disclosed
JAMES ROCK —
TAMI WAHL —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Legislation impacting the operation of pharmacy compounding, and access to compounded medications.

LobbyistCovered position, as disclosed
JAMES ROCK —
TAMI WAHL —

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.